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N-glycosylation proﬁling of plasma provides evidence for
accelerated physiological aging in post-traumatic stress disorder
M Moreno-Villanueva1,7, J Morath2,7, V Vanhooren3,4, T Elbert2, S Kolassa5, C Libert3,4, A Bu¨rkle1 and I-T Kolassa2,6
The prevalence of age-related diseases is increased in individuals with post-traumatic stress disorder (PTSD). However, the
underlying biological mechanisms are still unclear. N-glycosylation is an age-dependent process, identiﬁed as a biomarker for
physiological aging (GlycoAge Test). To investigate whether traumatic stress accelerates the aging process, we analyzed the
N-glycosylation proﬁle in n¼ 13 individuals with PTSD, n¼ 9 trauma-exposed individuals and in n¼ 10 low-stress control
subjects. Individuals with PTSD and trauma-exposed individuals presented an upward shift in the GlycoAge Test, equivalent
to an advancement of the aging process by 15 additional years. Trauma-exposed individuals presented an intermediate
N-glycosylation proﬁle positioned between severely traumatized individuals with PTSD and low-stress control subjects. In
conclusion, our data suggest that cumulative exposure to traumatic stressors accelerates the process of physiological aging.
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INTRODUCTION
In the aftermath of traumatic events, the probability of developing
post-traumatic stress disorder (PTSD), which is characterized by a
cluster of intrusive symptoms, avoidance behavior and hyper-
arousal,1 increases with the number of different traumatic event
types experienced.2,3 This cumulative effect of traumatic load is
presumably based on the development of a neuronal fear
network: the connectivity between nodes is strengthened and
the network is enlarged by every additional traumatic event
experienced.4
In addition to psychological suffering, traumatic stress also
increases the risk of developing somatic illnesses, such as
cardiovascular, inﬂammatory and autoimmune diseases.5 As a
result, trauma exposure is associated with premature mortality
and an increased risk for carcinogenesis.6–8 One underlying
biological mechanism might be that chronic stress is associated
with an accelerating process of cellular aging.9 Individuals with
PTSD not only show typical age-related diseases10,11 and report an
older subjective age than controls,12,13 but they even show
characteristics indicative of accelerated aging. For instance, naive
T lymphocytes decrease with age and are the lowest in
centenarians,14 and individuals with PTSD also show a reduction
in naı¨ve T lymphocytes.15 Next, the proportion of memory T
lymphocytes increases with normal aging,16,17 and individuals
with PTSD also display a higher proportion of memory T
lymphocytes compared with age-matched controls.15 Gene
expression of the pro-inﬂammatory cytokine interleukin-6 is
increased after menopause and andropause in elderly adults18—
and the concentration19 and spontaneous production20 of
interleukin-6 is enhanced in individuals with PTSD. C-reactive
protein, which is a marker for low-grade inﬂammation, is elevated
in women over the age of 60 years21and also in individuals with
PTSD.22 On a bio-molecular level, DNA damage increases with
age,23 and DNA damage, detected as DNA single-strand breaks,
also accumulates in individuals with PTSD.24 Contrary to
expectations, elevated levels of DNA damage are not related to
impaired DNA repair, but rather seem to accelerate DNA repair
capacity, as neither old people23 nor individuals with PTSD show
deﬁcits in DNA repair capacity;24 yet, DNA repair processes might
still be altered in individuals with PTSD and also with age,25 and
this should be investigated in more detail in future studies. Finally,
telomeres, which stabilize the end of chromosomes, gradually
shortened by advancing age in many cell types,26 and telomere
shortening is again also associated with childhood maltreatment27
and PTSD.28
N-glycosylation is an enzymatic process that produces sugar
chains covalently linked to macromolecules like proteins and
lipids. N-glycans present on proteins are oligosaccharides
covalently attached to protein at asparagine (Asn) residues by
an N-glycosidic bond mediating numerous biological functions. In
contrast to proteins, N-glycans are not controlled by the genome,
but secondary gene products and can be altered by environ-
mental inﬂuences.29 Previous studies identiﬁed nine prominent
N-glycan structures in human plasma, named peak 1 through peak
9.30 The concentration of N-glycans in human plasma varies with
age,31 and whereas N-glycan peak 1 (agalactosylated core-a-1,6-
fucosylated biantennary; NGA2F) increases with age, N-glycan
peak 6 (bigalactosylated core-a-1,6-fucosylated biantennary;
NA2F) decreases.32 The log ratio of these two N-glycans [log10
(peak1/peak6)], called GlycoAge Test, is a biomarker for physio-
logical aging and gives information beyond chronological age.33
Interestingly, juvenile patients with Cockayne syndrome, a
1Molecular Toxicology Group, Department of Biology, University of Konstanz, Konstanz, Germany; 2Center of Excellence for Psychotraumatology, Clinical Psychology and
Neuropsychology, University of Konstanz, Konstanz, Germany; 3Department for Molecular Biomedical Research, VIB, Ghent, Belgium; 4Department of Biomedical Molecular
Biology, Ghent University, Ghent, Belgium; 5SAP Switzerland AG, Ta¨gerwilen, Switzerland and 6Clinical and Biological Psychology, Institute of Psychology and Education,
University of Ulm, Ulm, Germany. Correspondence: Professor Dr A Bu¨rkle, University of Konstanz, Department of Biology, Chair of Molecular Toxicology, Box X911, Konstanz
78457, Germany or Professor Dr I-T Kolassa, Clinical and Biological Psychology, University of Ulm, Institute of Psychology and Education, Albert-Einstein-Allee 47, Ulm 89069,
Germany.
E-mail: alexander.buerkle@uni-konstanz.de or Iris.Kolassa@uni-ulm.de
7These authors contributed equally to this work.
Received 20 March 2013; revised 23 August 2013; accepted 8 September 2013
Citation: Transl Psychiatry (2013) 3, e320; doi:10.1038/tp.2013.93
& 2013 Macmillan Publishers Limited All rights reserved 2158-3188/13
www.nature.com/tp
progeroid disease that is due to a genetic deﬁciency in transcri-
ption-coupled nucleotide excision repair,34 show high values in
the GlycoAge Test.33
We hypothesize that trauma exposure might lead to accelerated
aging. We examined the N-glycosylation proﬁle in the plasma of
individuals with PTSD, of trauma-exposed individuals who were
not diagnosed with PTSD and of a low-stress control group. We
hypothesized that individuals with PTSD would present higher
values in the GlycoAge Test, compared with the low-stress control
group. Further, we hypothesized that trauma-exposed individuals




We analyzed the N-glycosylation proﬁle of 13 individuals (2 women, 11 men)
with PTSD (DSM IV-TR),1 in comparison with a high-stress (trauma-exposed
individuals: n¼ 9; 3 women, 6 men) and a low-stress (n¼ 10; 8 women, 2
men) control group. Individuals with PTSD were refugees living in Germany
(4 from Africa, 1 Balkan and Eastern Europe, 8 Middle East and Afghanistan)
with a history of severe war and torture experiences. Survivors of multiple
traumata commonly also exhibit depressive symptoms. In individuals with
PTSD, the average scores on the Hamilton rating scale (HAM-D)35 ranged
from 0 to 39, with 7 of the 13 patients reaching a threshold of 426.36
As non-PTSD subjects differed substantially in the number of traumatic
experiences, we divided this group by median split into a high-stress
(Trauma-exposed: 4 from Africa, 1 Balkan and Eastern Europe, 4 Middle
East and Afghanistan) group with substantial trauma exposure (traumatic
load: M¼ 1.18, s.d.¼ 0.63) and a low-stress group (3 from Africa, 2 Balkan
and Eastern Europe, 5 Middle East and Afghanistan) without substantial
trauma exposure (traumatic load: M¼ 0.23, s.d.¼ 0.09). The traumatic load
in individuals with PTSD was signiﬁcantly higher (traumatic load: M¼ 1.61,
s.d.¼ 0.49; F(2,29)¼ 25.88; Po0.0001). Traumatic load was speciﬁed by the
proportion of speciﬁc war and torture experiences, assessed by the Vivo
checklist of war, detention and torture events37 and general traumatic
event types, assessed by the Clinical Administered PTSD Scale (CAPS).38
Twelve subjects reported taking psychotropic medication: eight
individuals with PTSD (2 benzodiazepines, 5 antidepressants, 1 neuro-
leptics, 1 lithium), three trauma-exposed individuals (1 benzodiazepines, 2
antidepressants) and one control subject (benzodiazepines). To control for
possible effects of medication, we compared the N-glycosylation proﬁle of
individuals with PTSD with (n¼ 8) and without medication (n¼ 6).
Individuals with PTSD were recruited by the Center of Excellence for
Psychotraumatology. Control subjects were recruited through advertise-
ments, which were posted in town and university.
Exclusion criteria were comorbid psychological disorders (other than
major depression episode (MDE)), acute infections and chronic inﬂamma-
tory diseases. MDE was not used as an exclusion criterion because the
comorbidity of MDE in individuals with PTSD is high,39 and MDE
symptomatology overlaps with PTSD pathology in a wide range (for
example, diminished interest, restricted range of affect, difﬁculty with
falling or staying asleep, lack of concentration).
Psycho-diagnostic interviews took place at the Center of Excellence for
Psychotraumatology, University of Konstanz, Germany. Blood analyses
were performed in the Laboratory for Molecular Toxicology, University of
Konstanz, Germany, and the Department for Molecular Biomedical
Research, Ghent University, Belgium. The Ethics Committee of the
University of Konstanz approved the study. All study subjects signed an
informed consent and received a remuneration of 30h.
Psycho-diagnostic interview
Psycho-diagnostic interviews were conducted by trained clinical psychol-
ogists specialized in the ﬁeld of trauma. Whenever participants were not
ﬂuent in German or English, interviews were conducted with the help of
trained interpreters. Traumatic events, PTSD diagnosis and PTSD symptom
severity were assessed with the CAPS.38 Traumatic experiences were
assessed using the Vivo checklist of war, detention and torture
experiences.37 The Hamilton depression rating scale (HAM-D)35 was used
for quantiﬁcation of depressive symptoms. To exclude potential comorbid
psychiatric disorders, the Mini International Neuropsychiatric Interview
(MINI)40 was applied.
Clinical characteristics
Groups did not differ with respect to age. Individuals with PTSD
experienced signiﬁcantly more different traumatic event types and
showed higher traumatic load compared with low-stress controls. PTSD
symptom severity (CAPS score) and depressive symptoms (HAMD-D score)
were highest in individuals with PTSD. Trauma-exposed individuals were
between the two groups (Table 1).
Analysis of N-glycosylation
To standardize the time of blood collection, blood was always collected at
10:00 a.m. using Coagulation 9 NC Monovettes (Sarstedt, Germany). Blood
samples were coded to guarantee blinding of the laboratory staff. In a ﬁrst
step, blood plasma was isolated and quick-frozen at  80 1C at the
Laboratory for Molecular Toxicology, University of Konstanz. In a second
step, frozen plasma samples were shipped on dry ice to the Department
for Molecular Biomedical Research, Ghent University, Belgium for N-
glycosylation analysis. N-glycosylation was analyzed in 2 ml of plasma.
Nine N-glycan structures (peak 1—peak 9), which were identiﬁed to be
most prominent in previous studies,30 and the GlycoAge Test [log10
(peak1/peak6)],33 were measured using a DNA sequencing equipment
(3130 Genetic Analyzer; Applied Biosystems, Grand Island, NY, USA),
ﬂuorophore-assisted carbohydrate electrophoresis (DSA-FACE).41
Statistical analysis
Statistical analyses were performed using R 2.11.0,42 using an alpha level of
0.05. Group differences in clinical characteristics and in the N-glycosylation
proﬁle were analyzed using ANOVAs. Age, use of tobacco, psychotropic
medication and gender were included separately as covariates into the
model. The Akaike Information Criterion (AIC) was used for evaluating the
appropriateness of models,43 with the model without covariates having
the lowest AIC. In the case of signiﬁcant effects, t-tests were calculated for
post hoc comparison. Residuals in all models were tested for deviations
from the normal distribution. Residuals in the models of the GlycoAge Test,
the N-glycan peak 2, the N-glycan peak 8 and the N-glycan peak 9 were not
normally distributed; therefore, these variables were re-analyzed using
Table 1. Mean and s.d. of clinical characteristics, in n¼ 10 low-stress control subjects, n¼ 9 trauma-exposed individuals and n¼ 13 individuals with
PTSD
Variables Low-stress Controls Trauma-exposed PTSD Statistics P-value
M (s.d.) M (s.d.) M (s.d.)
Age 30.20 (8.94) 38.67 (14.05) 34.62 (6.80) F(2,29)¼ 1.73 0.19
CAPS 0.5 (1.58) 26.00 (23.54) 89.62 (18.20) F(2,29)¼ 84.11 o0.0001
Number different event types (CAPS) 3.2 (1.69) 7.56 (3.36) 8.85 (1.99) F(2,29)¼ 16.76 o0.0001
Traumatic loada 0.23 (0.09) 1.18 (0.63) 1.61 (0.49) F(2,29)¼ 25.88 o0.0001
HAM-D score 2.60 (6.13) 9.00 (12.16) 26.62 (10.53) F(2,29)¼ 18.14 o0.0001
Abbreviations: CAPS, clinical administered PTSD scale); M, mean; s.d., standard deviation. aTraumatic load was specified by the proportion of specific war and
torture experiences, assessed by the Vivo checklist of war, detention and torture events37 and general traumatic event types, assessed by the Clinical
Administered PTSD Scale (CAPS).38
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nonparametric statistics (Kruskal–Wallis test; for post hoc comparison
Mann–Whitney-U test). Correlations were analyzed using the Kendall Tau
rank correlation.
RESULTS
Individuals with PTSD and trauma-exposed individuals presented
higher values in the GlycoAge Test compared with low-stress
controls (w2¼ 7.00; P¼ .03; Table 2). There were signiﬁcant group
differences between the low-stress control group and individuals
with PTSD (W¼ 25; P¼ 0.01). Trauma-exposed individuals differed
neither signiﬁcantly from individuals with PTSD (W¼ 70; P¼ 0.47)
nor from controls (W¼ 22; P¼ 0.06), but were positioned in-
between these two groups. Interestingly, traumatic load was
positively correlated with the GlycoAge Test (t ¼ 0.41; P¼ 0.02,
Figure 1).
With respect to a possible effect of gender, we included gender
as an additional factor into the model and results did not change.
Further, there was no signiﬁcant main effect of gender
F(1,28)¼ 0.24; P¼ 0.63 and no signiﬁcant interaction between
group gender F(2,26)¼ 2.05; P¼ .15 in the GlycoAge Test.
Individuals with PTSD with psychotropic medication (n¼ 7;
median¼  0.33; range¼  0.53– 0.23) did not differ signiﬁ-
cantly in the GlycoAge Test (W¼ 22.0; P¼ 0.41) from individuals
with PTSD without medication (n¼ 6; median¼  0.51; range¼
 0.62 to  0.34).
In addition to the effect on GlycoAge Test, also in the N-glycan
peak 2 individuals with PTSD presented signiﬁcantly higher values
(w2¼ 6.04; P¼ 0.05). In post hoc tests, individuals with PTSD
(W¼ 30; P¼ 0.03) and trauma-exposed individuals (W¼ 20;
P¼ 0.04) differed signiﬁcantly from low-stress controls. There
were no signiﬁcant differences between PTSD and trauma-
exposed individuals (W¼ 65.5; P¼ 0.66; Table 2 and Figure 2).
Further, individuals with PTSD, surprisingly, presented
reduced values in N-glycan peak 7 (F(2,29)¼ 4.35; P¼ 0.02).
Individuals with PTSD differed signiﬁcantly from the low-stress
control group (t(11.9)¼ 2.75; P¼ 0.02), and trauma-exposed indivi-
duals were positioned in-between, but did not differ signiﬁcantly
from the PTSD or the low-stress control group (Table 2 and
Figure 3).
However, as we did not have a priori hypotheses for the N-
glycans peak 2 and peak 7, but rather made exploratory analyses,
we corrected these results for multiple comparisons. After a
stepwise Holm correction,44 group differences in the N-glycan
peak 2 and in the N-glycan peak 7 did not remain signiﬁcant.
The N-glycosylation of peaks 1, 3, 4, 5, 6, 8 and 9 did not
differ signiﬁcantly between individuals with PTSD and low- or
high-stress controls (Table 2).
Table 2. N-Glycans in PTSD, trauma-exposed and low-stress control subjects
Variables Low-stress controls (n¼ 10 ) Trauma-exposed (n¼ 9) PTSD (n¼ 13) Statistics P-value
M (s.d.) M (s.d.) M(s.d.)
Peak 1 6.46 (2.72) 8.28 (2.35) 8.48 (2.03) F(2,29)¼ 2.36 0.11
Peak 2 1.04 (0.51) 1.35 (0.34) 1.41 (0.44) w2¼ 6.04 0.05
Peak 3 6.99 (1.78) 7.17 (1.88) 7.69 (2.20) F(2,29)¼ 0.28 0.69
Peak 4 6.19 (1.43) 6.41 (1.31) 6.13 (1.42) F(2,29)¼ 0.11 0.89
Peak 5 40.31 (5.24) 40.80 (5.37) 40.35 (4.72) F(2,29)¼ 0.03 0.97
Peak 6 22.77 (1.78) 20.30 (2.87) 20.49 (3.35) F(2,29)¼ 2.44 0.11
Peak 7 6.39 (1.58) 5.63 (1.26) 4.91 (0.73) F(2,29)¼ 4.35 0.02
Peak 8 6.91 (1.75) 6.34 (1.96) 6.91 (1.75) w2¼ 0.52 0.77
Peak 9 1.77 (0.70) 2.48 (1.11) 1.97 (1.25) w2¼ 2.47 0.29
GlycoAge Test  0.58 (0.20)  0.40 (0.12)  0.39 (0.10) w2¼ 7.00 0.03
Abbreviations: M, mean; s.d., standard deviation; w2, Kruskal–Wallis test. Bold P-values indicate significance on an alpha level of 0.05 (two-sided).


















Figure 1. Scatterplot between the GlycoAge Test and Traumatic load
in n¼ 10 low-stress controls, n¼ 9 trauma-exposed and n¼ 13 PTSD
subjects. Higher values in the GlycoAge Test were positively
correlated with Traumatic load.




















Figure 2. Scatterplots in the N-glycan peak 2 from n¼ 10 low-stress
controls, n¼ 9 trauma-exposed and n¼ 13 PTSD subjects. Indivi-
duals with PTSD demonstrated significant higher values in the
N-glycan peak 2, compared with low-stress controls. Trauma-
exposed individuals were positioned between PTSD and the low-
stress control group.
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DISCUSSION
Individuals with PTSD and trauma-exposed individuals showed
increased values in the GlycoAge Test, which is a biomarker for
physiological aging.33 In the general population, values in the
GlycoAge Test are stable until 40 years of age and then increase
continuously, with the highest values being observed at the age of
90–99 years.33 The GlycoAge Test proﬁle in individuals with PTSD
and trauma-exposed individuals with a mean age of 35 years is
similar to the GlycoAge Test proﬁle in people with a mean age of
about 50 years, in a Belgian population.33 This shift in N-
glycosylation strongly indicates that traumatic stress may
accelerate the process of physiological aging.
The N-glycosylation proﬁle depends not only on age, but also
on sex.44 However, we did not ﬁnd a signiﬁcant inﬂuence of
gender or group gender in the GlycoAge Test. Reasons may be
that our sample included also relatively young people in the age
between 15 and 30 years old, who were not present in the study
of Ding et al.,45 as well as of course traumatized participants,
which was not the focus of Ding et al.45 Further, as our sample size
was limited and men and women were not equally distributed
between groups, further research is needed to focus on gender
speciﬁc alterations in individuals with PTSD.
Given that there are interactive effects between stress, age and
immune functions,46 it is noteworthy that the N-glycosylation
proﬁle in older people is associated with a state of IgG-mediated
low-grade inﬂammation.47 Low-grade inﬂammation and changes
in the immunoglobulin regulation, in turn, have been reported in
individuals with PTSD as well.48 Alterations in N-glycosylation may
therefore not only be a marker of physiological aging but might
actually contribute to the pathogenesis of aging itself47 via
inﬂammation processes, which can be caused by traumatic stress.49
Further, individuals with PTSD presented higher values in the
N-glycan peak 2, although these results did not remain signiﬁcant
after statistical corrections. The N-glycans peak 1 and peak 2 are
reported to increase gradually with age, whereas the N-glycan
peak 6 is reported to decrease with age.32 We see the same
picture in individuals with PTSD, even though group differences in
the N-glycan peak 1 and peak 6 were not statistically signiﬁcant
(Table 2).
Interestingly, we found a reduction in the N-glycan peak 7 in
individuals with PTSD, although this effect did not withstand
statistical corrections. However, we report this effect because this
ﬁnding might be interesting for future studies. To the best of our
knowledge, there has been only one study on the N-glycan peak 7
so far, which was found to be decreased in patients with
hepatocellular carcinoma compared with liver cirrhosis patients,
with a negative correlation between the N-glycan peak 7 and
tumor development.30 At the present state of knowledge, it is
difﬁcult to pinpoint a mechanistic link that could explain the
concordant N-glycan peak 7 effect in these two quite diverse
disease conditions.
Limitation of the study: there was no possibility to control for
unfavorable environments (unhealthy food, poor medication, etc.),
which might inﬂuence the effect of accelerated aging. However,
interestingly, traumatic load was positively correlated with the
GlycoAge Test (t¼ 0.41; P¼ 0.02, Figure 1). This argues against the
hypothesis that exposure to unfavorable living conditions is a
main driver of this effect; on the other hand, trauma exposure in
itself is an unfavorable environment. Thus, the inﬂuence cannot be
controlled for.
In conclusion, we present evidence that traumatic stress leads
to an accelerated process of physiological aging, as revealed by a
shift in the N-glycosylation proﬁle that is typical of persons with
higher age, which is possibly mediated by a state of low-grade
inﬂammation.
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